MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.12.24

MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.12.24 Stock

DE000ME9H239

Market Closed - Bid/Ask 11:32:19 2024-07-16 EDT			After market 14:39:21
1.22 ^EUR	+0.83%		1.29	+5.74%

Current month	-2.42%
1 month	-1.63%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MADRIGAL PHARMACEUTICALS, INC.

Chart MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/250/0.02/20.12.24

Latest news about MADRIGAL PHARMACEUTICALS, INC.

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	11:17am	MT
Non Alcoholic Fatty Liver Disease Pipeline 2024 \| Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceutical	07-10	AQ
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	06-28	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11

More news

Quotes 5-day view

Date	Price	Change
24-07-16	1.22	+0.83%
24-07-15	1.21	-6.92%
24-07-12	1.3	-5.80%
24-07-11	1.38	+0.73%
24-07-10	1.37	-4.20%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 11:32 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	MADRIGAL PHARMACEUTICALS, INC.
Issuer	Morgan Stanley
WKN	ME9H23
ISIN	DE000ME9H239
Date issued	2024-03-01
Strike	250 $
Maturity	2024-12-20 (157 Days)
Parity	50 : 1
Emission price	1.44 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.93 €
Lowest since issue	0.41 €
Delta	0.69x
Omega	2.818
Premium	14.67x
Gearing	4.06x
Moneyness	1.111
Difference Strike	-29.77 $
Difference Strike %	-11.91%
Spread	0.09 €
Spread %	6.92%
Theoretical value	1.260
Implied Volatility	74.23 %
Total Loss Probability	49.18 %
Intrinsic value	0.5096
Present value	0.7504
Break even	318.64 €
Theta	-0.02x
Vega	0.01x
Rho	0.01x

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

280 USD

Average target price

365.3 USD

Spread / Average Target

+30.50%

Consensus